Urothelial bladder cancer is the most common cancer of the urinary system 1 . In the UK, it is the ninth most common cancer and is responsible for 3% of cancerrelated deaths 2 . The incidence of urothelial bladder cancer is higher in males than in females and increases with age, with more than half of new cases diagnosed in patients older than 75 years of age. Approximately one-third of patients present with muscle-invasive bladder cancer (MIBC) at diagnosis and require a more aggressive treatment than those with non-muscleinvasive bladder cancer (NMIBC). Traditionally, radical cystectomy, which includes surgical removal of the bladder and other pelvic organs followed by reconstruction of the urinary tract, has been the standard-of-care treatment for MIBC 3 . However, radical cystectomy is associated with potential complications (severe blood loss, infections, paralytic ileus and issues with wound healing) 4 and long-term consequences that could have a negative effect on a patient's quality of life (QOL) 5 . Over the past decade, curative oncological strategies have moved from extensive surgery to organ-preserving treatments in different cancer types, ranging from head and neck malignancies to anal cancer. Trimodality bladder-preserving treatment (TMT) comprises maximal transurethral resection of the bladder tumour (TURBT) followed by radiotherapy and concurrent radiosensitizing treatment, thereby allowing patients to keep their own bladders. Data from meta-analyses and propensity-matched analyses have now led to an increasing acceptance that patients undergoing TMT and radical cystectomy have comparable long-term clinical outcomes 6, 7 . Importantly, patients should be informed about treatment options in a manner that will enable them to choose the optimal strategy that is most suitable for them. Advances in different aspects of nonsurgical oncology, including adaptive and image-guided radiotherapy techniques and prognostic and predictive biomarkers, will enable the delivery of personalized management plans.
Urothelial bladder cancer is the most common cancer of the urinary system 1 . In the UK, it is the ninth most common cancer and is responsible for 3% of cancerrelated deaths 2 . The incidence of urothelial bladder cancer is higher in males than in females and increases with age, with more than half of new cases diagnosed in patients older than 75 years of age. Approximately one-third of patients present with muscle-invasive bladder cancer (MIBC) at diagnosis and require a more aggressive treatment than those with non-muscleinvasive bladder cancer (NMIBC). Traditionally, radical cystectomy, which includes surgical removal of the bladder and other pelvic organs followed by reconstruction of the urinary tract, has been the standard-of-care treatment for MIBC 3 . However, radical cystectomy is associated with potential complications (severe blood loss, infections, paralytic ileus and issues with wound healing) 4 and long-term consequences that could have a negative effect on a patient's quality of life (QOL) 5 . Over the past decade, curative oncological strategies have moved from extensive surgery to organ-preserving treatments in different cancer types, ranging from head and neck malignancies to anal cancer. Trimodality bladder-preserving treatment (TMT) comprises maximal transurethral resection of the bladder tumour (TURBT) followed by radiotherapy and concurrent radiosensitizing treatment, thereby allowing patients to keep their own bladders. Data from meta-analyses and propensity-matched analyses have now led to an increasing acceptance that patients undergoing TMT and radical cystectomy have comparable long-term clinical outcomes 6, 7 . Importantly, patients should be informed about treatment options in a manner that will enable them to choose the optimal strategy that is most suitable for them. Advances in different aspects of nonsurgical oncology, including adaptive and image-guided radiotherapy techniques and prognostic and predictive biomarkers, will enable the delivery of personalized management plans.
In this Review, we examine the main curative treatment options in MIBC by comparing TMT and radical cystectomy and discussing the role of neoadjuvant and adjuvant systemic treatments, the importance of radiosensitization, recent advancements in radiotherapy techniques in MIBC and the discovery of imaging and tissue biomarkers and their potential prognostic and predictive roles.
Organ preservation in bladder cancer: an opportunity for truly personalized treatment , Peter J. Hoskin 1, 3 and Ananya Choudhury 1, 2 Abstract | Radical treatment of many solid tumours has moved from surgery to multimodal organ preservation strategies combining systemic and local treatments. Trimodality bladderpreserving treatment (TMT) comprises maximal transurethral resection of the bladder tumour followed by radiotherapy and concurrent radiosensitizing treatment, thereby sparing the urinary bladder. From the patient's perspective, the choice of maintaining quality of life without a negative effect on the chances of cure and long-term survival is attractive. In muscleinvasive bladder cancer (MIBC), the evidence shows comparable clinical outcomes between patients undergoing radical cystectomy and TMT. Despite this evidence, many patients continue to be offered radical surgery as the standard-of-care treatment. Improvements in radiotherapy techniques with adaptive radiotherapy and advances in imaging translate to increases in the accuracy of treatment delivery and reductions in long-term toxicities.
With the advent of novel biomarkers promising improved prediction of treatment response, stratification of patients for different treatments on the basis of tumour biology could soon be a reality. The future of oncological treatment lies in personalized medicine with the combination of technological and biological advances leading to truly bespoke management for patients with MIBC.
Curative treatment options
The two main treatment options available to patients with localized MIBC are radical cystectomy and TMT.
As the choice between TMT and radical cystectomy is an important one, the differences between the two treatment options and the guideline recommendations should be considered.
Radical cystectomy versus TMT. Radical cystectomy, which involves major abdominopelvic surgery performed under general anaesthesia followed by a prolonged recovery period, is associated with increased operative mortality in elderly patients (age ≥75 years) and can result in long-term changes in QOL to which all patients must adapt. Such QOL changes include the construction of a urostomy or neobladder and negative effects on sexual function. In the long term, 24% of patients with ileal conduits experience stomal problems, and a similar proportion of patients develop renal insufficiency (27%), bowel problems (24%) and urinary tract infections (24%) 8 . With respect to sexual function, a retrospective survey by the Department of Health in England found that, at 1-5 years after diagnosis, 88% of patients reported dissatisfaction with their sex life after radical cystectomy, whereas only 11% and 17% of patients reported such dissatisfaction following chemoradiotherapy and radiotherapy, respectively 5 . TMT comprises maximal TURBT followed by radiotherapy with concurrent administration of a radiosensitizing agent (often chemotherapy) 9 . Radical radiotherapy to the bladder involves 4-7 weeks of daily treatment and has the potential of causing tiredness, impaired sexual function and adverse effects related to the bladder and bowel (such as urgency, dysuria and proctitis) 10 . Indeed, a 2018 meta-analysis reported that late Radiation Therapy Oncology Group (RTOG) grade 3 pelvic toxicities, including urinary and gastrointestinal toxicities, occurred in 7% of patients following TMT 11 . Moreover, in the phase III BC2001 trial, which investigated radiotherapy with or without synchronous chemotherapy in patients with MIBC, late RTOG grade 3-4 pelvic toxicities were noted in 4.6% of patients who underwent chemoradiotherapy and in 5.2% of patients who received radiotherapy only at 2 years after completion of treatment 12 . TMT is also associated with a long-term negative effect on bladder function, specifically decreased bladder capacity in ~3% of patients 13 , and cystectomy for intractable bladder symptoms rather than tumour recurrence is required in 1-2% of patients 13, 14 . An important component of TMT is ongoing cystoscopic surveillance with the possibility of salvage cystectomy after disease recurrence, which might be necessary in ~7-15% of patients 3, 12, 14 . In addition, TMT was associated with a risk of NMIBC recurrence in 25% of patients who had complete response, who might require treatment 15 . Ideally, radical cystectomy and TMT should be compared in a prospective randomized controlled trial, but attempts to do so have been unsuccessful owing to poor patient accrual 16 . The early closure of the Selective bladder Preservation Against Radical Excision (SPARE) trial has been attributed to several factors, including the complexity of the patient referral and management pathways (which had multiple specialist teams and centres involved) and the importance of patient preference in a trial that randomizes patients to two distinctly different treatment options.
Large radical cystectomy series report 5-year overall survival (OS) metrics ranging from 40.2% to 58% [17] [18] [19] . Similarly, a meta-analysis showed that patients with MIBC undergoing TMT had good outcomes, despite its use in frail patients, with a complete response rate of 78% and 5-year OS of 56% 20 . In addition, a pooled analysis of six RTOG studies showed that the 10-year diseasespecific survival (DSS) was 65% in patients with MIBC following bladder preservation treatment 3 .
Various retrospective studies and propensity-matched analyses have attempted to compare the outcomes of patients receiving either treatment option. In a populationbased retrospective cohort study, the cancer-specific survival and OS of patients who underwent radical cystectomy and TMT were similar following adjustments for covariates 7 . Similarly, a meta-analysis of 29 TMT studies and 30 radical cystectomy studies found that the 5-year OS was 63% for TMT and 61% for radical cystectomy for patients with T2 disease (P = 0.30) and was 45% and 40%, respectively, for patients with >T2 disease (P = 0.36) 21 . Conversely, a cohort study from 2018 proposed the contrary -that TMT is associated with poorer OS and DSS than radical cystectomy 22 . However, patients in the TMT group had received a median of 18 fractions of radiotherapy, suggesting that more than half of patients who allegedly underwent TMT did not, in fact, have curative treatment and, therefore, did not undergo TMT. During the time period studied (December 2011 to December 2013), TMT tended to be recommended for frail patients who were unfit for surgery, a consideration that was also not adequately accounted for in this study.
A number of factors preclude patients from each treatment option. Patients with serious comorbidities (for example, cardiac issues and renal failure) might be unable to tolerate the general anaesthetic and physiological stress associated with major surgery, and some patients might be unable or unwilling to adapt to the lifestyle changes that are required after radical cystectomy. Similarly, patients with extensive carcinoma in situ (CIS), poor bladder function or obstruction to their kidneys might not be appropriate candidates for TMT. Moreover, patients who undergo TMT must be prepared for the ongoing cystoscopic surveillance and the ongoing
Key points
• Retrospective analyses show that appropriately selected patients with muscleinvasive bladder cancer undergoing trimodality bladder-preserving treatment and radical cystectomy have comparable treatment outcomes.
• Advancements in adaptive and image-guided radiotherapy techniques have improved the accuracy of treatment delivery.
• Biomarkers have the potential to aid treatment decisions; prognostic biomarkers might help to inform the need for treatment intensification whereas predictive biomarkers might have a role in specific treatment selection.
• A scientific approach to treatment stratification will enable truly bespoke management plans, empowering patients to make informed decisions, and could influence long-term outcomes and quality of life.
www.nature.com/nrurol risk, for a minority of patients, that cystectomy will be ultimately required in the event of recurrence or poor residual bladder function. A retrospective study of patients with MIBC treated with either radical cystectomy or TMT found that patients who received TMT had markedly better general QOL, bowel function and sexual function; had fewer concerns about the negative effects of cancer; and had similar urinary symptoms scores 23 . Toxicity rates between the two treatment options have also been reported in the SPARE trial; 70% of patients in the radical cystectomy arm had Common Terminology Criteria for Adverse Events (CTCAE) grade 3-4 toxicity compared with 36% of patients in the radiotherapy group (P = 0.038) 16 . The primary aim of radical treatment for MIBC is to maximize the chance of cure while maintaining a good patient QOL. As discussed, both radical cystectomy and TMT as curative treatment options might result in serious adverse effects and, therefore, the long-term effect on QOL is an important consideration.
Guideline recommendations. In the UK, specific recommendations in the National Institute for Health and Care Excellence (NICE) guidelines 24 , which provide evidence-based guidance for clinical practice, advocate that patents with MIBC are offered both radical cystectomy and TMT as curative treatment options. This set of guidelines specifies the need to discuss the evidence for each treatment option in terms of efficacy, potential toxicities and the influence on QOL. Surgery remains the most common option recommended to patients in Europe and the USA 25, 26 . The European Association of Urology (EAU) and American Association of Urology (AUA) guidelines recommend that patients who are fit should be offered radical cystectomy, reserving TMT for those who are less fit; this recommendation is reflected in real-world practice. In a survey of 277 radiation oncologists from the USA, 58% treated only 1-3 patients per year with TMT and 74% primarily treated patients who were deemed unfit for surgery with TMT 27 . Similarly, a survey of 32 Italian centres found that, in the 13 centres that responded, only 12 of 100 patients with bladder cancer treated with radiotherapy in a 1-year period received radiotherapy as a primary curative treatment 28 . The main difference between the guidelines is that NICE recommends that patients should be offered both options, whereas the EAU and AUA guidelines recommend radical cystectomy over TMT for fit patients.
The choice between TMT and radical cystectomy is a difficult one for patients and a controversial topic among clinicians. Ideally, level I evidence from phase III randomized controlled trials would help to inform future guidelines. However, previous attempts at such a study have been unsuccessful.
Systemic therapy
As distant metastases are the most common cause of treatment failure following local therapy 29 , systemic treatment (chemotherapy and immunotherapy) before or following definitive local treatment with radical cystectomy or TMT has a role in improving the long-term outcomes of patients with MIBC.
Neoadjuvant chemotherapy. A systematic review and meta-analysis from 2005 reported a 5% improvement in 5-year OS and a 9% improvement in 5-year DSS with the use of platinum-based neoadjuvant chemotherapy before radical cystectomy or radiotherapy 30 . Another early randomized controlled trial conducted by the Southwest Oncology Group (SWOG) compared the use of three cycles of neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) with no neoadjuvant treatment before radical cystectomy in patients with MIBC. Despite a nonsignificant improvement of 6% in 5-year OS in the MVAC group, the trial reported a statistically significant improvement in pathological complete response of 23% (P < 0.001) 31 . In 2011, a phase III International Collaboration of Trialists study randomized 976 patients with MIBC to receive either neoadjuvant chemotherapy with cisplatin, methotrexate and vinblastine (CMV) or no neoadjuvant chemotherapy before definitive treatment with radical cystectomy, perioperative radiotherapy or radiotherapy alone. This study demonstrated that neoadjuvant CMV led to a 6% improvement in 10-year OS (P = 0.037) 32 . As these studies were undertaken before the adoption of radiosensitizing agent treatment with radiotherapy, the role of neoadjuvant chemotherapy in this setting has yet to be adequately tested.
The RTOG 8903 group carried out a phase III clinical trial to evaluate the benefit of neoadjuvant chemo therapy with CMV before chemoradiotherapy, the findings of which suggested that neoadjuvant chemotherapy did not improve survival outcomes 33 . However, the study was closed to recruitment early owing to high rates of severe neutropenia and sepsis, and only 67% of patients recruited to the experimental arm completed treatment with no or minor protocol deviation. In the BC2001 trial, 31.3% of patients who received chemoradiotherapy had undergone prior neoadjuvant platinum-based chemotherapy, but this treatment did not seem to affect locoregional disease-free survival outcomes 12 .
The choice of neoadjuvant chemotherapy regimen has also evolved. The aforementioned prospective rando mized trials evaluated MVAC or CMV, but trials from the past two decades have increasingly investigated the use of gemcitabine and cisplatin (GC) owing to its favourable toxicity profile and the similarity in survival outcomes between GC and MVAC in a phase III study of patients with advanced or metastatic MIBC 34 . A retro spective study comparing GC and MVAC in the neoadjuvant setting demonstrated similar pathological and survival outcomes before radical cystectomy and superextended pelvic lymph node dissection 35 . In the past 10 years, dose-dense MVAC (ddMVAC) has replaced classic MVAC. Classic MVAC is administered in 4-week cycles whereas ddMVAC is delivered every 2 weeks with granulocyte colony-stimulating factor (G-CSF) in order to ameliorate the resulting myelosuppression, which enables the same dose of doxorubicin and cisplatin to be delivered in half the time. A further retrospective study reported similar outcomes with ddMVAC, classic MVAC and GC 36 , whereas another study suggested that ddMVAC yields better rates of complete pathologi cal response and survival than GC 37 .
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Considering the retrospective nature of these studies and the lack of randomization, a prospective trial would be helpful to determine the optimal neoadjuvant chemotherapy regimen.
Neoadjuvant chemotherapy has been shown to improve pathological response and survival outcomes before radical cystectomy and radiotherapy, but limited evidence exists for its role before chemoradiotherapy. However, given the role of systemic agents in reducing metastatic recurrence and given the published data showing that it is well tolerated before chemoradiotherapy 38 , neoadjuvant chemotherapy is standard treatment for bladder preservation in the UK 24 .
Neoadjuvant immunotherapy. Immunotherapy with immune checkpoint inhibitors (ICIs) is an emerging treatment modality in MIBC. In the metastatic setting, the anti-programmed cell death 1 (PD-1) antibody pembrolizumab was shown to improve median OS by 2.9 months and was associated with fewer treatment-related adverse events than chemotherapy in the second-line setting 39 . Accordingly, interest has been growing regarding the role of immunotherapy in the neoadjuvant setting 40 . Indeed, the phase II PURE-01 study investigated the role of neoadjuvant pembrolizumab before radical cystectomy and reported that patients with high PD-L1 expression had higher rates of complete pathological response with pembrolizumab than patients with low PD-L1 expression 41 . Despite the emerging trend towards exploring the potential of ICIs in various cancer types and although their role in the neoadjuvant setting in MIBC is certainly interesting, additional investigation is required before we can confidently establish its efficacy.
Adjuvant chemotherapy. Various attempts have been made to evaluate the benefit of adjuvant chemotherapy following radical cystectomy in patients with advanced bladder cancer. Unfortunately, however, early trial closure and poor accruals to these studies meant that firm conclusions could not be drawn [42] [43] [44] . A meta-analysis of 491 patients from six eligible trials found a 9% improvement in 3-year OS 45 . The authors concluded that, owing to various factors, the evidence was insufficient to change clinical practice. These factors include small patient numbers (491 patients; 238 deaths), the early closure of four trials, poor compliance with trial protocol (a large proportion of patients in two trials did not receive chemotherapy despite randomization to the chemotherapy group or received regimens other than those described in the protocols) and the lack of information about salvage chemotherapy for patients whose disease progressed. An updated meta-analysis has since been published but was based on summary statistics of each study as opposed to individual patient information. This meta-analysis found borderline statistical significance (P = 0.049) for improvement in OS with a 23% relative decrease in the risk of death when treated with adjuvant chemotherapy, but a large variation in the hazard ratio across the included studies was noted 46 . In addition, an exploratory analysis of a European Organisation for Research and Treatment of Cancer (EORTC) study that closed after recruitment of 284 of a planned 660 patients demonstrated a benefit in 5-year OS for adjuvant chemotherapy after radical cystectomy (79.5% versus 59.0%; P = 0.012) in node-negative patients, which constituted only 30% of recruited patients 44 . Owing to the lack of robust evidence in the adjuvant setting, neoadjuvant chemotherapy should continue to be the preferred option after radical cystectomy.
Developments in radiosensitization
Radical radiotherapy, with the addition of radiosensitizing agents to improve clinical outcomes, is central to bladder-preserving treatment. These radiosensitizing agents function in a synergistic manner with radiotherapy, increasing cell death and, therefore, improving the efficacy of treatment 47 . The different mechanisms of action of commonly used radiosensitizers are illustrated in Box 1. Radiosensitizers can be used either as single agents or in combination with other agents.
Box 1 | Mechanisms of action of radiosensitizers
Radiosensitizers are agents that function in a synergistic manner with radiotherapy to increase cell kill. Commonly used radiosensitizers include chemotherapy (single-drug or multidrug regimens) or other regimens such as hypoxia modification. Various phase II studies have investigated the use of different cisplatin-containing regimens (cisplatin alone, cisplatin plus 5-fluorouracil and cisplatin plus paclitaxel) as radiosensitizers in MIBC and have reported good complete response rates and long-term DSS that are comparable to that of radical cystectomy [48] [49] [50] [51] . However, these were relatively small studies with sample sizes of <100 patients. Patients in these studies were treated in a split-course manner, with assessment following an initial induction course of chemoradiotherapy, after which patients were selected for radical cystectomy or consolidation chemoradiotherapy on the basis of their response to induction treatment. These studies showed encouraging results at the time. Mak et al. 3 conducted a pooled analysis of these phase II trials and a phase III study and demonstrated that these prospective RTOG bladder-preserving protocols result in DSS comparable to that of cystectomy studies.
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Until the early 2000s, the only randomized clinical trial was a Canadian study that evaluated cisplatin monotherapy as a radiosensitizer 52 . This small study (n = 99) showed an improvement in both local control rate and OS with the addition of concurrent cisplatin to preoperative or definitive radiotherapy but had limited statistical power (3-year OS 47% versus 33%; P = 0.34). As cisplatin causes an increased risk of renal toxicity 53 , some clinicians have reservations about the use of cisplatin in patients with MIBC who might already have impaired renal function and other comorbidities.
Over the past 10 years, two large randomized trials from the UK comparing radiotherapy alone with the addition of radiosensitizing agents have been published. The phase III BC2001 trial reported an improvement in 2-year locoregional recurrence-free survival (RFS) from 54% to 67% (P = 0.03) and in 5-year OS from 35% to 48% (P = 0.16) with the addition of concomitant chemotherapy with 5-fluorouracil and mitomycin C to radiotherapy in patients with MIBC 12 . As cellular hypoxia increases resistance to radiation, the bladder carbogen nicotinamide (BCON) trial took a different approach to radiosensitization with the use of hypoxiamodifying agents instead of traditional chemotherapy agents. This trial showed that the addition of concurrent carbogen and nicotinamide to radiotherapy improved 3-year RFS from 43% to 54% (P = 0.06) and OS from 46% to 59% (P = 0.04) in patients with locally advanced disease 14 . Another agent that has been tested as a radiosensitizer for bladder cancer is gemcitabine. A phase II study of radiotherapy with concurrent gemcitabine in MIBC reported a complete response rate of 88% at first-check cystoscopy, with an organ preservation rate of 64% and an OS of 72% at 3 years 54 . In addition, a meta-analysis of eight published studies that evaluated concurrent gemcitabine and radiotherapy, which included a total of 190 patients with MIBC, described a 93% complete response rate at first-check cystoscopy within 12 weeks of completion of treatment and a 5-year OS of 59% 55 . The phase II NRG/RTOG 0712 study randomized patients to twice-daily radiation with cisplatin−5-fluorouracil or once-daily radiation with gemcitabine. The primary end point of 3-year distant-metastasis-free survival was reported to be >75% in both arms (78% versus 84%; P = 0.73), suggesting that outcomes were comparable 56 . In summary, the addition of radiosensitizers to radical radiotherapy of the bladder improves pati ent survival outcomes and should be considered in bladder-preserving treatments.
Radiotherapy to the bladder Central to TMT is the use of radical radiotherapy. As an organ that changes in shape, size and position, it is important to consider bladder motion, different techniques used to accommodate this variability and the benefit of advances in technology.
Challenges in bladder radiotherapy. Effective radiotherapy is dependent on delivering a curative dose of radiation to the macroscopic tumour and any potential microscopic extension while minimizing the dose to normal tissues. A course of radical radiotherapy for MIBC spans 4-7 weeks, depending on the fractionation protocol used. Before treatment, patients undergo CT imaging, known as the radiotherapy planning (RTP) scan, which enables identification of the clinical target volume (CTV) and organs at risk (OARs) and formulation of the optimal radiotherapy plan. Various radiotherapy protocols are in use internationally. The current convention in the UK is for the entire bladder to be treated with the same dose; therefore, the CTV includes the whole bladder and any extravesical extension of the tumour 12, 14 . Other treatment protocols might include an interim assessment of treatment response and, subsequently, reduction in the initial CTV to high-risk areas such as the tumour bed in patients with good response or proceeding to radical cystectomy in the event of inadequate response to initial treatment 3, 57 . Regardless of the radiotherapy plan and protocol used, the urinary bladder does not remain static during the entire course of radiotherapy, both between treatments (interfraction) and during each radiotherapy treatment (intrafraction) 58 . As a hollow organ that fills and empties on a regular basis, the shape, size and position of the bladder changes as a result of both internal and external pressures. To overcome this anatomical variation and ensure consistent coverage during treatment, a safety margin is added to the CTV, forming the planning target volume (PTV). Consequently, a potentially large amount of normal tissue is irradiated when the bladder is relatively empty, whereas some of the CTV could be missed if the bladder is very full; different radiotherapy departments have different drinking protocols to ameliorate this risk. When treatment starts, daily low-dose CT images, known as cone-beam CTs (CBCTs), are taken using the linear accelerator, and the bony anatomy on the RTP and CBCT scans is matched to ensure that the patient is treated in the same position. Various studies have investigated bladder motion during a course of radiotherapy. Apart from a small study of ten patients 59 , all other studies have concluded that maximum movement is in the anterior and cranial directions 58, [60] [61] [62] [63] (TaBle 1) . These studies have given us a better understanding of bladder movement, thereby providing an important basis for adaptive radiotherapy.
Adaptive radiotherapy. Different adaptive radiotherapy strategies that account for internal anatomical changes have been developed to improve target coverage while reducing unnecessary doses to surrounding tissues.
The 'plan of the day' (POD) strategy involves the formulation of multiple treatment plans, with the best plan selected on the day of treatment on the basis of the CBCT scan findings 64 . The treatment plans are designed on the basis of the patient's initial RTP scan, which is then modified to generate three isocentrically grown CTV plans -a small, medium and large plan (Fig. 1) . Before each day's treatment, a CBCT scan is performed and the most suitable plan that provides the best target coverage and the lowest dose to OARs is selected.
Several studies investigating the POD strategy have reported promising results regarding both feasibility and clinical outcomes [65] [66] [67] . Hafeez et al. 65 reported the outcomes of 55 patients who were unsuitable for daily radiotherapy or surgery and, therefore, treated with weekly hypofractionated radiotherapy using the POD approach. Among this group of patients who were unfit for radical treatment, 82% completed treatment and local disease control was achieved in 60% of patients, with a 4.3% rate of grade 3 late toxicity at 12 months. Improved normal tissue sparing with the POD method has also been demonstrated, with a 30% reduction in PTV in patients treated with adaptive radiotherapy compared with those treated using a nonadaptive approach 66 . Thus, adaptive radiotherapy has the potential to reduce the radiation dose to uninvolved surrounding tissues.
Another adaptive radiotherapy approach is known as the composite method 68 . In this approach, only one treatment plan is initially developed from the RTP scan. The patient is treated with this plan for the first few fractions of treatment, during which CBCT imaging is performed. These CBCTs are then averaged to generate a composite plan, which is used for subsequent fractions of treatment. This method corrects changes in bladder volume and position during the relatively longer time period between the RTP scan and the start of treatment than the POD approach, but it does not account for the random errors that occur with internal anatomical changes in the bladder between fractions or further changes in the bladder after the composite plan has been designed 67 
.
Despite an improvement over the use of a single plan, current adaptive radiotherapy approaches assume uniform bladder movement and expansion and do not consider intrafraction anatomical changes in the bladder. Furthermore, the generation of multiple radiotherapy 
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plans is labour-intensive and the daily choice of treatment plan is dependent on subjective assessments made by the treatment team. The RAIDER trial 69 is an ongoing phase II randomized study of adaptive radiotherapy in the radical treatment of MIBC that will investigate both the feasibility and influence of adaptive radiotherapy and dose-escalated adaptive tumour boost radiotherapy. Patients will be randomized to receive treatment on the standard single radiotherapy plan, adaptive radiotherapy with the POD approach or adaptive radiotherapy with the POD approach and doseescalated tumour bed boost. RAIDER is an important study as we continue to optimize the delivery of radical radiotherapy to improve patient outcomes. Patient recruitment is anticipated to end in June 2019.
MRI-guided radiotherapy.
CBCT imaging has enabled image-guided and adaptive radiotherapy and, in turn, has improved accuracy while a patient is on treatment. However, the image quality of this form of low-dose CT imaging is poor. Identification of the urinary bladder is relatively easy on CBCT imaging compared with other techniques such as MRI, but distinguishing soft tissue boundaries and accurately defining surrounding organs such as gastrointestinal structures and genitalia are more difficult with CBCT. By contrast, MRI produces superior soft tissue contrast, which offers consequent advantages for defining the target volume (CTV) and for daily evaluation of the anatomical structures for image guidance to ensure treatment reproducibility 70 (Fig. 2) . The next generation of linear accelerators combined with MRI are in clinical use. In addition to increased accuracy of anatomical coverage, improved visualization of soft tissues enhances identification of the tumour bed and, therefore, the potential delivery of high-dose boosts to this high-risk region 71 . T2-weighted MRI is one of the basic pulse sequences of an MRI scan and enables tumour tissues to be distinguished from normal bladder tissues 72 . Thus, this technique could enable the accurate identification and delineation of the tumour bed and high-risk regions for disease recurrence, leading to the potential for dose escalation in this area. Improved imaging on treatment would also improve the accuracy of radiotherapy delivery, enabling a reduction in expansion margins. The combination of these two advantages of T2-weighted MRI will enable the safe delivery of a high dose of radiation to the tumour bed.
A study of different MRI-guided adaptive radiotherapy techniques with regard to target coverage concluded that online re-optimization enables normal tissue sparing and should be considered for use in bladder cancer 73 . Patients in this study were treated with a hypofractionation regimen with one treatment each week. The study assessed target coverage and normal tissue sparing with respect to intrafraction motion by performing MRI scans at 2-minute intervals over 10-minute periods on a weekly basis, before each treatment, and applying different margins. The original treatment plan was then modified and adapted to the first MRI scan of that week. However, as this was a relatively small study with only nine patients (eight male patients and one female patient), further confirmatory studies are required.
The role of MRI-guided radiotherapy has been explored in other urological tumours. In a systematic review, McPartlin et al. 74 summarized the potential role of MRI in prostate radiotherapy, particularly in terms of the detection of intrafraction motion. MRIguided treatment has also shown encouraging results in other cancer types. For example, adaptive MRI-guided lung stereotactic body radiotherapy (SBRT) during each fraction of treatment has been found to provide better target conformality, thereby reducing the radiation dose to normal tissues 75 , whereas MRI-guided radiotherapy for re-irradiation of the head and neck region enabled the use of smaller CTV to PTV margins and improved accuracy 76 . Apart from anatomical information, MRI can also yield functional or biological information by imaging perfusion with the use of diffusion-weighted MRI (DWI) and oxygenation through blood-oxygen-leveldependent (BOLD) MRI. In turn, this technique has the potential of identifying areas that require high doses of radiation or patients who would benefit from hypoxia modification. and coronal (part c) CT images show the clinical target volume (CTV) plans for the 'plan of the day' (POD) adaptive bladder radiotherapy strategy. The initial treatment planning CT scan is modified to generate three isocentrically grown CTV plans -a small (blue), medium (purple) and large (green) plan. Before each day's radiotherapy treatment, a cone-beam CT scan is performed and the most suitable CTV plan that provides the best target coverage and the lowest dose to organs at risk is selected.
DWI provides quantitative information to aid tumour assessment 77 . DWI examines the diffusion of water molecules (Brownian motion) and reflects the cell density in the region examined. DWI differs from T2-weighted MRI, which provides information only on water content. As tumours have a greater cell density than normal tissues, they have a greater restriction in diffusion and a lower apparent diffusion coefficient (ADC). The ADC value might be useful in determining the aggressiveness of tumours, with a low ADC value found in MIBC and high-grade tumours 78 . DWI has also been shown to predict response to chemoradiotherapy, with a multivariate analysis having identified ADC value as the only statistically significant and independent predictor of sensitivity to chemoradiotherapy 79 . However, the limitations of DWI in bladder cancers represent an important consideration given that water diffusion is also impeded in noncancerous tissues such as neurological tissues, lymphatic tissues and areas of fibrosis, which can lead to misdiagnosis 80 . BOLD MRI exploits the difference in magnetism of deoxyhaemoglobin and oxyhaemoglobin. As deoxyhaemoglobin is paramagnetic and oxyhaemoglobin is diamagnetic, oxygenated blood appears brighter on T2-weighted MRI and, therefore, MRI sequences can be manipulated to be sensitive to the level of deoxyhaemoglobin. Thus, increasing blood oxygenation through the inhalation of carbogen (95% oxygen and 5% carbon dioxide) during a BOLD MRI scan can help to identify patients who would benefit from a hypoxia-modifying agent during treatment 81 . MRI-guided radiotherapy is still in its infancy. Online adaptive radiotherapy requires time and is labourintensive -unless the system is designed to generate an adaptive plan with deformable registration by warping the image obtained on treatment to fit the reference RTP image -and has the ability to perform effective and efficient software-based quality assurance 74 . In order to achieve software-based quality assurance in bladder radiotherapy, additional MRI-based studies examining bladder movement are needed, and adaptive radiotherapy strategies would need to be studied in large and varied patient populations.
Biomarkers
Over the past decade, unprecedented developments have been made in cancer genetics and genomics, enabling the exploration of molecular biomarkers in different cancer types, including MIBC. Importantly, noninvasive and invasive low-grade bladder cancers have been found to be different diseases with distinct pathogenetic pathways 82, 83 . Invasive tumours are believed to originate from CIS and are associated with dysregulation of the p53 and retinoblastoma (RB) pathways whereas noninvasive tumours are associated with FGFR3 and HRAS mutations [83] [84] [85] . Importantly, such molecular biomarkers might have prognostic and predictive value in bladder cancer and could inform treatment strategies.
Prognostic biomarkers. Prognostic biomarkers are biological features of a tumour that provide information about the general outcome of the disease and might help to identify patients who require treatment intensification. Importantly, despite predicting outcomes, prognostic biomarkers do not predict response to a specific treatment or intervention. Several potential prognostic biomarkers have been studied in urothelial bladder cancer, but they are not in routine clinical use as they have not been adequately validated and their clinical relevance has not yet been determined.
The tumour suppressor p53 is an important gatekeeper in G1-S cell cycle progression and has a key role in regulating cell growth and division 86 . Mutational inactivation of the TP53 gene results in an altered p53 phenotype, and TP53 alterations were found to be associated with increased risk of disease recurrence and a poor prognosis in patients with bladder cancer [87] [88] [89] . In bladder cancer, individual alterations in the levels of p53, cyclindependent kinase inhibitor 1 (also known as p21) and phosphorylated RB are associated with early recurrence and poor prognosis, whereas combinations of these alterations further enhance this prediction 90 . Indeed, the 5-year recurrence and survival were 93% and 8%, respectively, in patients with all three alterations compared with 23% and 70%, respectively, for those with a single alteration.
Gene expression profiling has been used to identify genes that might aid in bladder cancer diagnosis and in predicting recurrence and progression 82, [91] [92] [93] . Smith et al. 94 developed a 20-gene model that identified patients at high and low risk of lymph node metastasis, independent of age, gender, pathological tumour stage and lymphovascular invasion. As lymph node involvement is an important prognostic factor in bladder cancer recurrence and survival 95 , the ability to accurately predict lymph node metastases using this model, after adequate validation, could prove invaluable and could help to select patients for neoadjuvant chemotherapy before definitive treatment.
Interest has been growing in the role of the immune system in disease outcome and treatment response. Lymphocytic infiltration has been reported to be related to clinical outcome in various cancer types 96 . In a cohort of patients with MIBC undergoing radical chemoradiotherapy to the bladder, pretreatment lymphopenia was associated with poor outcome, a finding that was also observed in a separate cohort of patients with advanced bladder cancer undergoing palliative chemotherapy for advanced urothelial cancer 97 . PD-1, a cell surface receptor expressed on T cells, has gained importance in various cancer types. In line with its role in immune regulation, interaction of PD-1 with its ligands, such as programmed cell death 1 ligand 1 (PD-L1), results in downregulation of the immune response 98 . By expressing PD-1 ligands, tumours can exploit this immune checkpoint in order to evade immune detection. PD-L1 expression in bladder cancer has been shown to be associated with the risk of disease progression and decreased survival [99] [100] [101] . The use of ICIs targeting either PD-L1 or PD-1 in the metastatic setting has improved survival outcomes, particularly in patients with high PD-L1 expression 39, 102, 103 . Receptor tyrosine kinases (RTKs) regulate a number of cellular processes, including cell proliferation and differentiation, and have an active role in cancer development and progression 104 . Overexpression of human epidermal growth factor receptor 2 (HER2; also known as ERBB2) is associated with aggressiveness and poor prognosis in urothelial cancer, specifically lymphovascular invasion, disease recurrence and decreased DSS and OS 105, 106 . Prognostic biomarkers could possibly be used for the identification of patients with a poor prognosis who might require treatment intensification. However, although some biomarkers have both prognostic and predictive value (for example, PD-L1 expression), the prognostic value of most of the aforementioned biomarkers does not necessarily translate into predictive values; therefore, they might not be useful in guiding optimal treatment for an individual patient.
Predictive biomarkers. Predictive markers are biological features that predict response to an intervention or treatment. Despite still being at the developmental stage, predictive biomarkers have been identified that might aid patient selection for treatment options in bladder cancer, specifically for identifying patients who might respond well to radiotherapy or who might be better suited to surgery. However, further studies are now required to validate their predictive power and clinical value. Double-strand break repair protein MRE11 is involved in activation of the DNA damage response (DDR) by forming part of the MRE11-RAD50-NBS1 (MRN) complex, which has an important role in detecting doublestranded DNA damage and repair 107 . On the basis of their role in DDR, increased expression of MRN complex proteins would be expected to predict poor radiosensitivity, but different studies have concluded the opposite. The expression of MRE11 has been shown to be predictive for DSS following radical radiotherapy in both a test and validation cohort, with high MRE11 expression being associated with improved 3-year DSS in patients with MIBC after radiotherapy. This predictive value could be due to the relationship between low MRE11 expression and impaired checkpoint arrest and/or reduced apoptosis, resulting in increased radioresistance 108 . In the same study, MRE11 expression was found not to be associated with survival outcomes in patients who underwent radical cystectomy, a finding that has been further validated in a separate patient cohort 109 . Thus, MRE11 expression might be a useful predictive biomarker for stratifying patients to receive either surgery or bladder-preserving treatment. However, further validation of these findings in other cohorts has been disappointing owing to problems associated with assay reproducibility 110 ; therefore, MRE11 is not in current routine clinical use as a biomarker for patient selection.
The RTOG has reported that patients with HER2 + MIBC have a poor response to chemoradiotherapy; analysis of tumour samples from 55 patients enrolled in four RTOG bladder cancer studies revealed that HER2 expression status was associated with response rate following chemoradiotherapy 111 . In a biomarkerselective, nonrandomized study, patients with HER2 + MIBC were treated with anti-HER2 antibody trastuzumab in addition to chemoradiotherapy with paclitaxel, whereas HER2
-patients were treated with chemoradiotherapy only. Complete response rates were similar between groups (72% in HER2 + group versus 68% in HER2 -group) despite expectations that response rates would be lower in HER2 + patients 112 . This study was small (n = 76), and the radiosensitizing regimen used was non-standard, but the findings suggest the possibility of using HER2 status as a predictive biomarker for the addition of trastuzumab in order to improve outcomes in this patient group.
In addition to concurrent chemoradiotherapy, another option for radiosensitization in TMT is the use of hypoxia modification instead of chemotherapy. As a step towards biological stratification for the choice of radiosensitizer, retrospective analysis of tumour samples from the phase III BCON study (which evaluated the addition of concurrent carbogen and nicotinamide to radiotherapy) has enabled exploration of associations between tissue biomarkers and clinical outcomes and led to the identification of a number of potentially important predictive biomarkers for response to concurrent hypoxia modification. Specifically, necrosis, carbonic anhydrase IX (CAIX), hypoxia-inducible factor 1α (HIF1α) and a 24-gene signature have been shown to predict improved outcomes in patients treated with carbogen and nicotinamide. Eustace et al. 113 examined a variety of histopathological features in tumour samples from 231 patients enrolled in the BCON trial and found that necrosis and expression of the hypoxia marker CAIX independently predicted OS benefit from hypoxia modification. Another study that evaluated HIF1α expression by immunohistochemistry in tumour samples showed that patients with high HIF1α expression who were treated with hypoxia modification in combination with radiotherapy had a marked improvement in local relapse-free survival compared with those treated with radiotherapy alone, whereas no improvement was observed with hypoxia modification in patients with low HIF1α expression 114 . Similarly, a 24-gene signature that identified hypoxic MIBC tumours predicted benefit from the addition of hypoxia modification to radiotherapy 93 . In summary, a number of different biomarkers that predict response to bladder-preserving treatments in MIBC have been identified, mostly using retrospective data from randomized controlled trials, but few have been validated. With appropriate validation, these predictive biomarkers could aid clinicians and patients in the decision between treatment options and in formulating appropriate management plans. Biomarkers that predict response to radical cystectomy will be invaluable and could enable the development of algorithms to aid clinical decision-making regarding definitive treatment options (Fig. 3) .
Conclusions
Advances in TURBT techniques, radiotherapy delivery and supportive care over the past decade have improved the outcomes of patients with bladder cancer receiving organ preservation treatments 3, 57 . As discussed in this Review, meta-analyses and retrospective studies have suggested that response rates and survival outcomes of patients undergoing radical cystectomy and TMT are comparable. Thus, patients should be offered both options. Unfortunately, despite the potential influence on QOL, treatment choice is currently largely dependent on the centre at which the patient is treated 115 and the clinician's usual practice. We must look to exploit the ability to stratify patients using predictive biomarkers and improve the accuracy of radiotherapy delivery with new technologies, which will hopefully enable informed shared decision-making by clinicians and patients, thereby improving access of bladder preservation treatments to appropriate patients. When counselling patients and discussing potential treatment plans, a scientific approach will allow the clinician to offer patients truly bespoke management plans that are based on robust evidence. Importantly, this method would empower patients to make informed decisions on treatment choice that would have an effect on their long-term outcomes and QOL. The algorithm depicts a putative example illustrating the potential of a personalized treatment strategy using validated biomarkers. In the future, the expression of a predictive biomarker for trimodality bladder-preserving treatment (TMT) might help patients and clinicians decide between TMT and radical cystectomy. Furthermore, as discussed in the main text, predictive biomarkers to hypoxia modification such as double-strand break repair protein MRE11, carbonic anhydrase IX (CAIX), necrosis and a 24-gene hypoxia signature might also aid further decision with regard to choice of radiosensitizers. Importantly , this model is highly speculative and the listed biomarkers have not been adequately tested and should not be used in clinical practice until additional biomarker validation studies have been carried out.
www.nature.com/nrurol
